Paul Bravetti

Paul Bravetti is a seasoned executive in the pharmaceutical and biotechnology sectors, currently serving as both Chief Executive Officer and Chief Operating Officer at Brenus Pharma since April 2020, focusing on innovative oncology solutions. Prior experience includes roles as Regional Medical Advisor for Takeda Oncology, where significant contributions were made to the launch of Alunbrig and TAK788, and as Senior Marketing Manager for Servier's hypertension portfolio, successfully leading product launches in the APAC region. Earlier roles at Roche Pharmaceuticals encompassed various marketing and product management positions in nephrology and transplantation, contributing to the launch of targeted therapies. Paul's educational background includes a Doctor of Pharmacy from Université de Lorraine and a Master of Science in Marketing from HEC Paris.